SEC Form 4 · accession 0001127602-17-006607
Bioverativ Inc. · BIVV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Coelho Rogerio Vivaldi
Officer — EVP, Chief Global Therapeutics
Period of report
Feb 14, 2017
Accepted (ET)
Feb 16, 2017 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681689
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Feb 14, 2017 | A | 21,344 | A | — | — | Common Stock | 21,344 | 21,344 | D |
| Non-Qualified Stock OptionF3 | $44.51 | Feb 14, 2017 | A | 56,514 | A | — | Feb 14, 2027 | Common Stock | 56,514 | 56,514 | D |
| Non-Qualified Stock OptionF4 | $44.51 | Feb 14, 2017 | A | 113,028 | A | — | Feb 14, 2027 | Common Stock | 113,028 | 113,028 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2The restricted stock units vest in three equal annual installments beginning on February 14, 2018.
- F3This option vests in three equal annual installments beginning on February 14, 2018.
- F4This option vests in full on the third anniversary of the date of grant.